title: Clinical outcomes of osteomyelitis patients infected with methicillin-resistant Staphylococcus aureus USA-300 strains.
abstract: Methicillin-resistant Staphylococcus aureus (MRSA) USA-300 strains have emerged as an important cause of community-acquired infections. These strains have been recognized as an etiology of osteomyelitis but data on their incidence and outcomes are limited. We retrospectively studied the incidence and clinical outcomes of MRSA USA-300 osteomyelitis in patients at the University of Louisville Hospital and the Henry Ford Health System between January 2007 and March 2008. Pulsed-field gel electrophoresis was used to determine USA type. Clinical outcomes were defined as management success versus failure at 12 months. Chi-square tests, Fisher exact tests, and Mann-Whitney tests were used to compare patient characteristics on the basis of clinical outcomes and USA type. Of the 50 patients with MRSA osteomyelitis, 27 (54%) had the USA-300 strain. Clinical failure was identified in 22% (6/27) of the patients with MRSA USA-300 and in 30% (7/23) of the patients with MRSA non-USA-300 osteomyelitis (P = .509). Our results showed that MRSA USA-300 is a significant etiology of MRSA osteomyelitis. With current surgical and medical management, outcomes of patients with MRSA USA-300 osteomyelitis are similar to those of patients with MRSA non-USA-300 osteomyelitis.
authors.affiliation: University of Louisville, Louisville, Kentucky 40202, USA.
authors.forename: P
authors.initials: P
authors.lastname: Peyrani
authors.forename: M
authors.initials: M
authors.lastname: Allen
authors.forename: D
authors.initials: D
authors.lastname: Seligson
authors.forename: C
authors.initials: C
authors.lastname: Roberts
authors.forename: A
authors.initials: A
authors.lastname: Chen
authors.forename: N
authors.initials: N
authors.lastname: Haque
authors.forename: M
authors.initials: M
authors.lastname: Zervos
authors.forename: T
authors.initials: T
authors.lastname: Wiemken
authors.forename: J
authors.initials: J
authors.lastname: Harting
authors.forename: D
authors.initials: D
authors.lastname: Christensen
authors.forename: R
authors.initials: R
authors.lastname: Ramirez
mesh_terms: D000046:Academic Medical Centers; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D015331:Cohort Studies; D003646:Debridement / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010019:Osteomyelitis / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology* / Q000628:therapy*; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents